<DOC>
	<DOC>NCT00542789</DOC>
	<brief_summary>The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers</brief_summary>
	<brief_title>Comparative Efficacy &amp; Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Duodenal Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
	<criteria>Medical history of gastric and/or duodenal ulcer A diagnosis of a chronic condition (rheumatoid arthritis, osteoarthritis, lumbago,etc) that requires daily NSAID use,at least 20 years of age Having gastric or duodenal ulcer in active or healing stage according to the Sakita/Miwa classification History of esophageal, gastric or duodenal surgery Having severe liver disease or chronic renal disease</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>gastrointestinal</keyword>
	<keyword>GI</keyword>
	<keyword>NSAID</keyword>
	<keyword>Japan</keyword>
	<keyword>Japanese</keyword>
	<keyword>Gastric ulcer</keyword>
	<keyword>duodenal ulcer</keyword>
</DOC>